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Background: JM-1232(-) is a novel anesthetic agent which acts through gamma-aminobutyric acid receptors. Cerebral
pial vascular effects of JM-1232(-) are unknown. We thus evaluated topical and intravenous effects of JM-1232(-) on
cerebral pial microvessels in rabbits, and the extent to which carbon dioxide (CO2) reactivity is preserved.
Methods: Closed cranial windows were used to visualize cerebral pial circulation in 29 Japanese white rabbits. In the first
experiment, the cranial window was superfused with increasing concentrations of JM-1232(-): 10-11, 10-9, 10-7, 10-5 mol/L,
n = 8 per concentration. In the second experiment, we examined the effects of an intravenous bolus of 1 mg/kg bolus of
JM-1232(-), followed by the continuous infusion at 0.3 mg/kg/minute on cerebral pial vascular alteration (n = 9). In the
third, we examined CO2 reactivity of cerebral pial vessels under JM-1232(-) (n = 6) or sevoflurane anesthesia (n = 6).
Results: Topical application of JM-1232(-) did not change pial venular diameter, and constricted arterials only at the
highest concentration. Intravenous administration of JM-1232(-) produced cerebral pial constriction which gradually
diminished over time. Under intravenous administration of JM-1232(-) and inhaled sevoflurane, diameters of vessels
increased in parallel with CO2 partial pressure. Slopes of linear regression and correlation coefficients in arterioles and
venules were comparable for JM-1232(-) anesthesia and sevoflurane anesthesia.
Conclusions: Topical application of JM-1232(-) had little effect on cerebral pial vessels. Intravenous administration
produced vasoconstriction of cerebral pial arterioles and venules, however those changes were clinically unimportant. In
addition, JM-1232(-) did not impair CO2 responsiveness. At least from the perspective of vascular reactivity, JM-1232(-) thus
appears safe for neurosurgical patients.
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Benzodiazepines, which reduce both cerebral blood flow
(CBF) and cerebral metabolic rate (CMR) proportionally
[1,2], are often used for sedation and anesthesia in
neurosurgical patients. JM-1232(-), a novel anesthetic
agent, is sedative and hypnotic via activation of the
benzodiazepine site of a gamma-aminobutyric acid type
A (GABAA) receptors, although JM-1232(-) is not a
benzodiazepine [3]. The drug appears to possess a wide
therapeutic index and is thus promising as an intraven-
ous anesthetic [4].* Correspondence: ishiyama@yamanashi.ac.jp
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unless otherwise stated.The relationship between benzodiazepines and CBF is
well established. However, the direct in vivo effect of
JM-1232(-) on cerebral pial vessels has not been evalu-
ated previously, nor is the effect of intravenous adminis-
tration on pial vessel diameter established. We therefore
evaluated the in vivo effects of topical and intravenous
JM-1232(-) on cerebral pial microvessels in rabbits using
the cranial window technique. We also evaluated the ef-
fect of JM-1232(-) on carbon dioxide (CO2) reactivity of
cerebral pial vessels.Methods
The Ethics Committee on Animal Research, University
of Yamanashi, Yamanashi, Japan, approved this study.
Experiments were performed on 29 Japanese white rab-
bits weighing 2.8-3.5 kg. An intravenous catheter wasl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion infused at 10 mL/kg/h. The animals were anesthe-
tized with intravenous administration of pentobarbital
sodium (20 mg/kg) or inhalation of sevoflurane.
Anesthesia was maintained with an infusion of pento-
barbital sodium (5 mg/kg/h) or sevoflurane (4%).
Muscle relaxants were not used.
The animals were tracheostomized and their lungs
were mechanically ventilated with oxygen using volume
controlled ventilator ACE3000 (Acoma medical industry,
Tokyo, Japan). Initial tidal volume was 30-40 ml/kg and
respiratory rate was 20-30 beats/min. End-tidal CO2
(ETCO2) was continuously monitored (Vamos, Dräger
medical, Tokyo, Japan). A catheter inserted to femoral
artery allowed continuous monitoring of mean arterial
blood pressure (MAP) and blood sampling. Based on
ETCO2 measurements, the tidal volume and respiratory
rate were adjusted to maintain arterial carbon dioxide
partial pressure (PaCO2) between 30 and 50 mmHg. The
animals’ core body temperature, rectal temperature, was
maintained at 39 ± 1°C with a heating blanket.
A closed cranial window was used to visualize the
cerebral pial microcirculation. Each rabbit was placed in
the sphinx posture. The scalp was retracted and a 0.8-
cm-diameter hole was made at the parietal bone. After
bipolar coagulation of dural vessels, the dura and arach-
noid membranes were cut and a thin ring of plastic was
positioned over the hole and secured with bone wax and
dental acrylic. The space under the window was filled
with artificial cerebrospinal fluid (aCSF), and three poly-
ethylene catheters were inserted into the plastic ring.
One catheter was attached to a reservoir bottle con-
taining aCSF. The aCSF was suffused at 0.1 mL/min.
Two other catheters served as an inlet for study drug so-
lutions and an outlet for aCSF. The level of the outlet
was maintained approximately 5-6 cm above the window
to maintain intracranial pressure. The volume of fluid
below the window was between 0.5 and 0.7 mL. The
composition of aCSF was Na+ 151 mEq/L, K+ 3.5 mEq/
L, Ca2+ 2.5 mEq/L, Mg2+ 1.3 mEq/L, HCO3
- 25 mEq/L,
urea 40 mg/dL, and glucose 65 mg/dL [5].
The study was divided into three parts: the first evalu-
ated the direct effects of JM-1232(-) on cerebral pial ves-
sels, the second determined the effects of intravenous
administration of JM-1232(-) on cerebral pial vessels,
and the third considered the effect of JM-1232(-) on
CO2 reactivity of cerebral pial vessels).
In the first experiment (n = 8), anesthesia was induced
with intravenous administration of pentobarbital sodium
(20 mg/kg), and was maintained with an infusion of
pentobarbital sodium (5 mg/kg/h). JM-1232(-) (Maruishi
Pharmaceutical, Osaka, Japan) was dissolved in aCSF to
obtain concentrations of 10-11, 10-9, 10-7, 10-5 mol/L so-
lutions. After a stabilization period, control values forcerebral pial arteriolar and venular diameters and vari-
ous laboratory data including MAP, heart rate (HR), rec-
tal temperature, arterial blood gas tensions and pH,
plasma electrolytes, glucose and lactate concentration
were recorded.
The cranial window was superfused with escalating
concentrations of JM-1232(-) in aCSF. Superfusion rate
was initially set at 30 mL/h for 2 min. Because space
under the window was approximately 0.5 mL, super-
fusion rate at 0.5 mL/min for 2 min was sufficient to
clear aCSF in the window. Subsequently, infusion rate
was decreased to 6 mL/h for 5 min. This ensured a
steady-state superfusion. We measured the diameters of
cerebral pial vessels, MAP, HR, and rectal temperature,
arterial blood gas tensions, pH, plasma electrolytes, glu-
cose and lactate concentration once, 7 minutes after ap-
plication of each JM-1232(-) concentration. The window
was then flushed with aCSF for 30 minutes before ad-
ministration of the next concentration, and the super-
fusion rate was set at 30 mL/h,
In the second set of experiment (n = 9), we examined
the effects of intravenous administration of JM-1232(-)
on cerebral pial vasculature. In a preliminary experi-
ment, we determined that 1 mg/kg of JM-1232(-)
followed by a continuous infusion at 0.3 mg/kg/min in-
duced sleep and produced a bispectral index (BIS, proc-
essed EEG) of 70-80 which is consistent with moderate
sedation. Data from the manufacturer indicates that the
hypnotic dose of JM-1232(-) is 1 mg/kg for monkeys,
corresponding to an effective plasma concentration of
600 ng/ml. The hypnotic dose for rats is 0.7 mg/kg, corre-
sponding to an effective plasma concentration of 300 ng/
ml. In rats, a continuous infusion of JM-1232(-) at
0.3 mg/kg/min produces plasma concentrations of at
least 600 ng/mL within a few minutes. Plasma
concentration-time curve shows accumulation effect and
the steady-state concentration at 6 μg/ml is produced
within 30 min. Moreover, plasma concentration of JM-1232
(-) after stopping the continuous infusion at 0.3 mg/kg/min
was maintained the hypnotic concentration 30 min or
more. We thus used a bolus of 1 mg/kg JM-1232(-)
followed by a continuous infusion at 0.3 mg/kg/min for the
second and third set of studies.
Anesthesia was induced with sevoflurane, and was
maintained with sevoflurane (4%). After a cranial win-
dow was established, sevoflurane was stopped. We con-
firmed that the end-tidal sevoflurane concentration
decreased to almost 0% in 30 min. When animals started
to move or 20 min after the discontinuation of sevoflur-
ane, JM-1232(-) was given a bolus of 1 mg/kg intraven-
ously, followed by a continuous infusion at 0.3 mg/kg/
min. Control values for cerebral pial arteriolar and venu-
lar diameters and various laboratory data including
MAP, HR, rectal temperature, arterial blood gas tensions
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tration were recorded just before the start of JM-1232(-).
The measurements of cerebral pial vascular diameters and
laboratory examinations were performed 10, 20, 40, and
60 minutes after initiating the JM-1232(-) infusion. JM-
1232(-) was then stopped, and the cerebral pial vascular
diameters and laboratory data were obtained 5, 10, and
30 min after the discontinuation of JM-1232(-).
In the third set of experiment, we examined CO2 reactiv-
ity of cerebral pial vessels during intravenous administra-
tion of JM-1232(-) (n = 6) or inhaled sevoflurane (n = 6). In
the JM-1232(-) anesthetized group, anesthesia was induced
with JM-1232(-) 1 mg/kg bolus followed by 0.3 mg/kg/
min. A cranial window was established. Then, control
values for cerebral pial arteriolar and venular diameters
and various laboratory data were recorded under normal
ventilation (PaCO2 40 ± 5 mmHg) at 0, 10, and 20 mi-
nutes. Hypercapnia (PaCO2: 50 ± 5 mmHg) was then in-
duced by hypoventilation and cerebral pial vessel
diameter and laboratory data were recorded at 0, 10,
and 20 minutes. And finally, hypocapnia (PaCO2: 30 ±
5 mmHg) was induced by hyperventilation and mea-
surements repeated at 0, 10, and 20 minutes. In the
sevoflurane anesthetized group, anesthesia was induced
and maintained with sevoflurane (4%). After cranial
window implantation, pial vascular responses to hypo-
capnia (PaCO2, 30 ± 5 mmHg), normocapnia (PaCO2,
40 ± 5 mm Hg) and hypercapnia (PaCO2, 50 ± 5 mmHg)
were studied as described above.
The diameters of several cerebral pial arterioles and
venules were measured in each cranial window using a
digital video analyzer (VH Analyzer VH-H1A5, Key-
ence, Osaka, Japan) on a personal computer that was
attached to a microscope (VH-5000, Keyence, Osaka,
Japan) via video capture unit (VH-E500, Keyence,
Osaka, Japan). We selected diameters of arterioles and
venules between 50 and 100 μm. Data from the pial
views were stored on the computer hard disk for subse-
quent analysis after the experiments. MAP, HR, rectal
temperature, arterial blood pH, PaCO2, arterial oxygen
tension (PaO2), and plasma concentrations of Na
+, K+,
glucose and lactate in each experimental group, topical
concentration-dependent effects of JM-1232(-), and
CO2 responses of cerebral pial vessels were compared
using analysis of variance (ANOVA) and post hoc
Tukey tests. Cerebral pial vascular responses to topical
JM-1232(-) were examined by paired t-test. Cerebral
pial vascular responses to intravenous administration
of JM-1232(-) were examined via ANOVA and Dunnett’s
tests for post hoc comparisons. Responsiveness of CO2
data was assessed using linear regression, with slopes
compared multivariably. Values are represented as
means ± SDs; A P value less than 0.05 was considered
statistically significant.Results
Body weight of the eight rabbits in the topical experiment
was 3 ± 0.3 kg; it was 3.1 ± 0.1 kg in the nine rabbits of the
intravenous administration of JM-1232(-) experiment, and
3 ± 0.1 kg in twelve animals for the CO2 response experi-
ment. In the topical experiment, MAP, HR, rectal
temperature, arterial pH, PaCO2, PaO2, base excess (BE)
and plasma Na+, K+ glucose and lactate concentrations did
not change significantly during the experimental period
(Table 1). Absolute control diameter of arterioles was 76 ±
20 μm, and venules was 80 ± 23 μm. Topical application of
JM-1232(-) at 10-11 to 10-7 mol/L did not produce any sig-
nificant change on cerebral pial vessels. JM-1232(-) only at
10-5 mol/L induced constriction on cerebral pial arterioles
(Figure 1A). In cerebral pial venules, JM-1232(-) did not
exert any significant effect (Figure 1B).
In the experiment of intravenous administration of JM-
1232(-), decreases in MAP and HR were observed, and
lactate and glucose concentration increased during admin-
istration of JM-1232(-). However, rectal temperature, ar-
terial pH, PaCO2, PaO2 and plasma Na
+, K+ did not
change significantly (Table 2). Absolute control diameter
of arterioles was 61 ± 19 μm and venules was 66 ± 25 μm.
Cerebral pial arterioles and venules were significantly con-
stricted after discontinuation of sevoflurane (Figure 2A,
B). Intravenous administration of JM-1232(-) induced
cerebral pial arteriolar constriction at the time between 5
and 60 minutes (Figure 2A) and venular constriction be-
tween 10 and 60 minutes (Figure 2B). After discontinu-
ation of JM-1232(-), constrictions of cerebral pial
arterioles and venules were attenuated.
In the CO2 response experiment, HR, MAP, rectal
temperature BE, PaO2, plasma Na
+, K+, and lactate did
not change significantly (Table 3). In the JM-1232(-)
group, control diameter of arterioles was 62 ± 16 μm and
venules was 74 ± 15 μm. In the sevoflurane group, con-
trol diameter of arterioles was 65 ± 17 μm and venules
was 76 ± 11 μm. The percentage changes in the diame-
ters of cerebral arterioles was similar with JM-1232(-) [%
change in diameter = 0.83∙CO2 – 37, r = 0.67] and sevo-
flurane [% change in diameter = 0.82∙CO2 – 32, r = 0.56]
as a function of CO2 partial pressure. Figure 3A shows
that the slopes did not differ significantly. Likewise, the
percentage change in diameters of cerebral venules was
similar with JM-1232(-) [% change in diameter =
0.80∙CO2 – 35, r = 0.61] and sevoflurane [% change in
diameter = 0.67∙CO2 – 27, r = 0.56] as a function of CO2
partial pressure. Figure 3B shows that the slopes did not
differ significantly.
Discussion
Kuribayashi et al. reported that JM-1232(-) at between
10-4 and 5 x 10-4 mol/L depressed central respiratory ac-
tivity, and estimated that the hypnotic dose was less than
Table 1 Physiologic variables during topical application of JM-1232(-)
JM-1232(-) concentration (mol /L) (n=8)
10-11 pre 10-11 post 10-9 pre 10-9 post 10-7 pre 10-7 post 10-5 pre 10-5 post
MAP (mmHg) 100 ± 5 100 ± 9 101 ± 10 102 ± 11 103 ± 11 101 ± 11 102 ± 11 102 ± 11
HR (bpm) 247 ± 12 251 ± 16 245 ± 17 246 ± 16 247 ± 18 245 ± 19 241 ± 19 245 ± 28
RT(°C) 39.5 ± 0.4 39.4 ± 0.4 39.4 ± 0.4 39.5 ± 0.5 39.5 ± 0.4 39.4 ± 0.5 39.4 ± 0.5 39.4 ± 0.5
pH 7.40 ± 0.05 7.40 ± 0.04 7.41 ± 0.03 7.40 ± 0.05 7.42 ± 0.02 7.42 ± 0.03 7.41 ± 0.03 7.41 ± 0.03
PaCO2 (mmHg) 43 ± 2 43 ± 3 43 ± 2 42 ± 2 41 ± 2 42 ± 2 42 ± 2 42 ± 3
PaO2 (mmHg) 472 ± 62 484 ± 43 489 ± 41 482 ± 54 482 ± 44 478 ± 66 498 ± 39 501 ± 35
Na+ (mEq/L) 142 ± 1 142 ± 1 142 ± 1 141 ± 1 142 ± 1 141 ± 1 141 ± 2 142 ± 2
K+ (mEq/L) 3.0 ± 0.4 3.0 ± 0.2 3.0 ± 0.2 3.0 ± 0.2 3.0 ± 0.2 3.0 ± 0.3 3.1 ± 0.3 3.0 ± 0.3
BS (mg/dl) 134 ± 18 133 ± 16 133 ± 10 132 ± 9 132 ± 10 130 ± 15 129 ± 9 128 ± 13
BE 2.4 ± 1.7 1.7 ± 2.3 1.4 ± 2.7 1.5 ± 2.6 1.8 ± 2.3 2.0 ± 2.1 1.6 ± 2.1 1.6 ± 2.1
Lactate (mmol/L) 1.5 ± 0.6 1.4 ± 0.5 1.5 ± 0.6 1.6 ± 0.7 1.6 ± 0.7 1.6 ± 0.7 1.7 ± 0.7 1.8 ± 0.6
Data are expressed as means ± SDs. There are no difference between each application period.
BS: blood glucose concentration, HR: heart rate, MAP: mean arterial pressure, RT: rectal temperature.
BE: Base excess.
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JM-1232(-) in the rabbit is probably well under 10-5 mol/L.
They also reported that the concentration of JM-1232(-) in
the brain tissue after the injection of anesthetic dose may
be lower than that of propofol in rats. We reported that
clinically relevant propofol concentration in rabbits would
be 1.2 x 10-6 mol/L or less [7]. Topical application of JM-
1232(-) at concentrations of 10-7 to 10-6 mol/L, as in our
study, thus correspond to clinically relevant therapeutic
plasma concentrations in rabbits. This concentration of
JM-1232(-), though, had no direct effect on cerebral pial
vessels.
Topical JM-1232(-) had only slight constrictive effects
on cerebral pial arterioles diameters, even at a concen-
tration of at 10-5 mol/L. Our results contrast with those
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Figure 1 The effects of topical application of JM-1232(-) on cerebral p
Data are percent change in diameters compared with pre-drug measurem
had no effect on cerebral pial venules. (n = 8). * P < 0.001 compared with pmidazolam produced dose-dependent relaxation in
smooth muscle in human gastroepiploic artery in vitro.
We previously reported that propofol had no effect on
cerebral pial arteriolar or venular tone at clinical con-
centrations [7]. Nevertheless, propofol has direct effects
upon systemic arterial and venous vascular tone [9], in-
dicating that systemic and cerebral arterioles respond
differently to some drugs.
At the higher concentrations of JM-1232(-), there may
be significant penetration of the drug into the cerebral
cortex and consequently systemic absorption. Further-
more, local absorption could locally inhibit neural trans-
mission with consequent reductions in blood flow.
Consistent with this theory, topical application of con-
centrated dexmedetomidine produced systemic actions
























Concentrations of JM-1232(-) (-log mol/L)
11 9 7 5
B
ial arteriolar (A) and venular (B) diameters. Values are means ± SDs.
ents. JM-1232(-) at 10-5 mol/L constricted cerebral pial arterioles but
re-application of JM-1232(-).
Table 2 Physiologic variables during IV JM-1232(-) application (n = 9)
Pre Soff10 control JM10 JM40 JM60 JMoff10 JMoff30
MAP (mmHg) 82 ± 15 92 ± 13 94 ± 91 87 ± 12 83 ± 12* 78 ± 12* 82 ± 11* 90 ± 10
HR (bpm) 279 ± 15 273 ± 15 277 ± 21 260 ± 13 249 ± 27 239 ± 22* 272 ± 17 277 ± 16
RT(°C) 39.6 ± 0.8 39.6 ± 0.8 39.6 ± 0.7 39.6 ± 0.7 39.6 ± 0.7 39.6 ± 0.7 39.5 ± 0.6 39.6 ± 0.6
pH 7.44 ± 0.02 7.42 ± 0.03 7.41 ± 0.03 7.40 ± 0.03 7.40 ± 0.03 7.42 ± 0.03 7.39 ± 0.03 7.39 ± 0.03
PaCO2 (mmHg) 38 ± 3 40 ± 2 40 ± 2 41 ± 4 40 ± 3 40 ± 2 40 ± 2 40 ± 1
PaO2 (mmHg) 441 ± 38 455 ± 25 458 ± 27 456 ± 37 455 ± 33 451 ± 25 453 ± 28 454 ± 27
Na+ (mEq/L) 141 ± 1 141 ± 1 141 ± 1 142 ± 1 141 ± 1 142 ± 1 142 ± 2 142 ± 1
K+ (mEq/L) 3.8 ± 0.2 3.8 ± 0.2 3.8 ± 0.3 3.7 ± 0.2 3.7 ± 0.2 3.6 ± 0.1 3.7 ± 0.1 3.8 ± 0.2
BS(mg/dl) 123 ± 8* 122 ± 7* 128 ± 13 140 ± 12* 144 ± 13* 155 ± 19* 160 ± 19* 158 ± 20*
BE 2.3 ± 3.1 2.1 ± 2.7 2.2 ± 2.4 1.9 ± 2.6 1.9 ± 2.2 0.7 ± 2.6* 0.0 ± 2.8* 0.3 ± 2.1*
Lactate (mmol/L) 2.8 ± 0.7 2.9 ± 0.5 2.8 ± 0.4 3.4 ± 0.6* 4.2 ± 1.0* 5.0 ± 1.5* 5.4 ± 1.5* 5.2 ± 1.2*
Data are expressed as means ± SDs. *P < 0.05 compared with control.
S: sevoflurane, JM: JM-1232(-), Control: just before JM-1232(-) infusion, off 10: 10 min after sevoflurane discontinuation, JM 10, 40, and 60: 10, 40, 60 min after intravenous
JM-1232(-) administration, JMoff 10, 30: 10 and 30 min after JM-1232(-) discontinuation, MAP: mean arterial pressure, HR: heart rate, RT: rectal temperature, BS: blood glucose
concentration, BE: Base excess.
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cerebral pial arterioles. Like benzodiazepines, JM-1232
(-) has sedative and hypnotic properties that are medi-
ated by benzodiazepine sites of GABAA receptors [8].
Benzodiazepines such as midazolam and diazepam re-
duced both cerebral CBF and CMR [2]. CMR is associated
with a proportional change in CBF. Our preliminary experi-
ment and our previous study [11] showed that JM-1232(-)
decreases BIS values. BIS is commonly used to measure
hypnotic effect, and appears reliable in rabbits [12]. It
therefore seems likely that JM-1232(-) decreased neural ac-
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Figure 2 The effects of intravenous administratin of JM-1232(-) on ce
are means ± SDs. Data are percent change in diameters compared with contro
arteriolar and venular diameters constricted significantly. After intravenous adm
the time between 5 min and 60 min (A) and venular constriction was induced
cerebral pial arteriolar (A) and venular (B) constriction were attenuated. S = sevoWe also observed that intravenous administration of
JM-1232(-) induced cerebral pial vasoconstriction that
gradually reversed after discontinuation of the drug. Un-
published data from the pharmaceutical company indi-
cate that plasma concentrations of JM-1232(-) are
maintained at hypnotic concentrations was for at least
30 minutes after stopping a continuous infusion at
0.3 mg/kg/min. Presumably, hypnotic level decreased
after stopping JM-1232(-), with consequent increases in
CMR and CBF. Consistent with this theory, vasodilation
of cerebral arterioles and an increase in CBF were ob-
served when flumazenil was given to antagonize midazo-
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rebral pial arteriolar (A) and venular (B) diameters. (n = 9) Values
l (just before JM-1232(-) infusion). After discontinuation of sevoflurane,
inistration of JM-1232(-), cerebral pial arteriolar constriction was induced at
between 10 min and 60 min (B). After discontinuation of JM-1232(-),
flurane. * P< 0.05, † P< 0.01, compared with control.
Table 3 Physiologic variables during the study of CO2 reactivity on cerebral pial vessels under JM-1232(-) (n = 6) or
sevoflurane anesthesia (n = 6)
JM Control JM 40 ± 5 JM 50 ± 5 JM 30 ± 5 S Control S 40 ± 5 S 50 ± 5 S 30 ± 5
MAP (mmHg) 72 ± 13 72 ± 8 69 ± 7 63 ± 6 99 ± 7 95 ± 4 98 ± 4 95 ± 7
HR (bpm) 249 ± 24 260 ± 14 272 ± 12 256 ± 4 242 ± 28 244 ± 45 248 ± 36 244 ± 43
RT(°C) 39.8 ± 0.3 39.7 ± 0.3 39.9 ± 0.2 40.1 ± 0.1 40.2 ± 0.5 40.2 ± 0.5 40.0 ± 0.7 40.1 ± 0.6
pH 7.42 ± 0.04 7.42 ± 0.05 7.32 ± 0.04† 7.54 ± 0.05† 7.40 ± 0.02 7.42 ± 0.03 7.33 ± 0.02* 7.51 ± 0.02*
PaCO2(mmHg) 42 ± 2 42 ± 2 55 ± 2† 31 ± 2† 41 ± 2 41 ± 2 50 ± 2* 32 ± 2*
PaO2 (mmHg) 451 ± 26 469 ± 15 437 ± 58 474 ± 25 480 ± 27 488 ± 32 476 ± 32 489 ± 34
Na+ (mEq/L) 140 ± 2 139 ± 3 140 ± 2 139 ± 2 141 ± 1 141 ± 1 142 ± 1 142 ± 2
K+ (mEq/L) 3.6 ± 0.4 3.7 ± 0.3 3.9 ± 0.4 3.9 ± 0.4 3.6 ± 0.4 3.6 ± 0.3 3.6 ± 0.2 3.4 ± 0.3
BS (mg/dl) 126 ± 15 119 ± 11† 120 ± 11 114 ± 8 135 ± 22 130 ± 15 135 ± 18 137 ± 12
BE 2.8 ± 4.0 3.0 ± 4.0 2.2 ± 2.7 2.8 ± 4.3 1.2 ± 2.0 1.2 ± 2.0 1.5 ± 2.2 1.0 ± 2.2*
Lactate (mmol/L) 1.7 ± 0.4 2.0 ± 0.6 2.3 ± 0.9 3.3 ± 1.0† 3.4 ± 2.0 3.2 ± 1.8 3.4 ± 1.9 4.1 ± 2.5
Data are expressed as means ± SDs. *P < 0.05 compared with S control. †P < 0.05 compared with JM control.
Control: the time PaCO2 40 mmHg was confirmed by blood gas data, 30 ± 5, 40 ± 5, 50 ± 5: PaCO2 was 30 ± 5, 40 ± 5, and 50 ± 5 mmHg, JM:JM-1232(-), S:
sevoflurane, MAP: mean arterial pressure, HR: heart rate, RT :rectal temperature, BS: blood glucose concentration, BE: Base excess.
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JM-1232(-) thus appears to cause anesthesia which re-
duces metabolic rate, and therefore pial vessel flow when
the drug is discontinued, anesthesia dissipates and pial
flow returns.
In the third study, we examined CO2 responsiveness
experiment under JM-1232(-) at 0.3 mg/kg/min intra-
venously and 1 MAC sevoflurane. Because CO2 respon-
siveness is well preserved under sevoflurane anesthesia
[15], we used sevoflurane as a control. As expected from
previous work, CO2 responsiveness was preserved under
sevoflurane anesthesia in the present study. We demon-
strated that arteriolar and venular linear regression
slopes and correlation coefficients were comparable be-
tween JM-1232(-) anesthesia and sevoflurane anesthesia.























Figure 3 Scatterplot and linear regression of cerebral pial arteriolar (A
and sevoflurane anesthetized rabbits. (n = 6) Slopes of linear regression
between JM-1232(-) anesthesia and sevoflurane anesthesia. Solid line shows t
sevoflurane. ●JM-1232(-) anesthesia, Δ sevoflurane anesthesia.to CO2 should be similar between JM-1232(-) anesthesia
and sevoflurane anesthesia. Our results may be compat-
ible with the previous result showing that CO2 respon-
siveness of the regional cerebral blood flow in the
cerebral cortex preserved after the application of benzo-
diazepines such as midazolam [16]. We verified that
CO2 responsiveness should be well preserved during
anesthesia with JM-1232(-).
JM-1232(-) has sedative and anesthetic properties,
however, sedative and anesthetic doses of JM-1232(-) for
rabbits have not been well documented. Masamune
et al. [11] reported that intravenous administration of
JM-1232(-) at 0.01 mg/kg/min and 0.1 mg/kg/min com-
bined with 0.2 minimum alveolar concentration of iso-
flurane reduced bispectral index (BIS) values in rabbits.























) and venular (B) CO2 response in JM-1232(-) anesthetized (n = 6)
and correlation coefficients in arterioles and venules were comparable
he regression for JM-1232(-), and dashed line represents the regression for
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Although the BIS algorithm of humans may not be ap-
plicable to rabbits, JM-1232(-) at 0.01 mg/kg/min prob-
ably has sedative property and that at 0.1 mg/kg/min has
anesthetic property in rabbits if isoflurane would be in-
haled. In our study, because we did not use isoflurane,
we used BIS to determine hypnotic dose of JM-1232(-).
As a result, we employed the higher dose of JM-1232(-)
at 0.3 mg/kg/min. Shirasaka et al. [3] proposed that the
intravenous administration of JM-1232(-) decreased
MAP via activation of benzodiazepine GABAA receptors.
In addition, because MAP decreased after intravenous
administration of JM-1232(-) at 0.3 mg/kg/min, benzodi-
azepine GABAA receptors could have been activated ef-
fectively in our study. The sole application of JM-1232(-)
at 0.3 mg/kg/min might produce sufficient anesthesia for
rabbits.
We observed that intravenous administration of JM-1232
(-) decreased MAP and decreased HR in rabbits. JM-1232
(-) induced decrease in MAP attributed to a decrease in
sympathetic nerve activity in rats [3] Moreover, Moriyama
et al. reported that JM-1232(-) dose dependently relaxed
smooth muscle in human gastroepiploic artery [8]. De-
crease in MAP and HR caused by IV JM-1232(-) may be
mediated by systemic vasodilation induced by blockade of
sympathetic nerve activity and direct vasodilatory action.
JM-1232(-) did not affect the baroreceptor reflex [3]. In
baroreceptor reflex, the decrease in MAP results in an in-
crease in HR. However, HR decreased after IV JM-1232(-).
Blockade of sympathetic nerve activity caused by JM-1232
(-) appears to overcome the baroreflex and as a result, HR
decreased.
Plasma lactate concentrations were elevated in our
second serious of experiments, but not in the third, al-
though the same dose of JM-1232(-) was used in each.
In the third series, anesthesia was induced and main-
tained with JM-1232(-) throughout the experiment. On
the other hand, JM-1232(-) was started when animals
started to move or 20 min after the discontinuation of
sevoflurane in the second experiment. Animals may have
suffered some stress at the period between discontinu-
ation of sevoflurane and start of JM-1232(-) in the sec-
ond experiment.
In the experiment of intravenous administration of
JM-1232(-), when the end-tidal sevoflurane concentra-
tion decreased after discontinuation of sevoflurane, pial
arterioles and venules were significantly constricted.
This result indicates that sevoflurane per se has cerebro-
vascular dilator action on cerebral pial vessels. Our re-
sult concurs with Iida and coworkers’ who showed that
sevoflurane significantly dilated cerebral pial arterioles
in a concentration-dependent manner [17].
Cerebral circulation is regulated by metabolic regula-
tory mechanisms, chemical regulatory mechanisms,autoregulation, the autonomic nervous, and vascular endo-
thelial regulation. Arterial pH, PaCO2, and PaO2 have sub-
stantial influences on cerebral vascular resistance and blood
flow. Moreover, physiologic and pharmacologic stimuli may
well have different upstream and downstream effects on the
cerebral vasculature. Topical application of drugs into a cra-
nial window allowed us to evaluate the direct effect of drugs
without the changes in CMR and CBF consequent to sys-
temic administration. Although venules actively dilate in re-
sponse to topical nitroglycerin [18], topical JM-1232(-) did
not alter venular diameter, suggesting that venules were pas-
sive conduits under the condition of our study.
We started JM-1232(-) when animals started to move or
20 min after the discontinuation of sevoflurane to avoid a
period with no anesthesia. We thus do not have a true con-
trol in which vessel diameters were measured after sevo-
flurane was discontinued but without the addition of JM-
1232(-). Beginning the JM-1232 infusion at 20 minutes thus
may not reflect the true baseline for some animals.
Conclusion
In conclusion, we evaluated the in vivo effects of JM-
1232(-) on cerebral pial vessels in rabbits using the cra-
nial window technique. Topical application of JM-1232
(-) had little effect on cerebral pial vessels though high
dose JM-1232(-) produced slight constriction. Intraven-
ous administration produced vasoconstriction on cere-
bral pial arterioles and venules, however those changes
were clinically trivial. And finally, CO2 responsiveness
with JM-1232(-) was similar to that during sevoflurane
anesthesia. At least from the perspective of vascular re-
activity, JM-1232(-) thus appears safe for neurosurgical
patients.
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